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During 2003–2011, we recruited 1,065 patients of all ages 
admitted to Mahosot Hospital (Vientiane, Laos) with sus-
pected central nervous system (CNS) infection. Etiologies 
were laboratory confirmed for 42.3% of patients, who mostly 
had infections with emerging pathogens: viruses in 16.2% 
(mainly Japanese encephalitis virus [8.8%]); bacteria in 
16.4% (including Orientia tsutsugamushi [2.9%], Leptospira 
spp. [2.3%], and Rickettsia spp. [2.3%]); and Cryptococcus 
spp. fungi in 6.6%. We observed no significant differences 
in distribution of clinical encephalitis and meningitis by bac-
terial or viral etiology. However, patients with bacterial CNS 
infection were more likely to have a history of diabetes than 
others. Death (26.3%) was associated with low Glasgow 
Coma Scale score, and the mortality rate was higher for 
patients with bacterial than viral infections. No clinical or 
laboratory variables could guide antibiotic selection. We 
conclude that high-dependency units and first-line treat-
ment with ceftriaxone and doxycycline for suspected CNS 
infections could improve patient survival in Laos.
Central nervous system (CNS) infections, which can be caused by a number of different viruses, bacteria, 
fungi, and parasites, cause substantial disease and death in 
Southeast Asia (1). The etiologies of these infections are 
usually confirmed in <50% patients globally (2,3). Conven-
tionally, most CNS infections are classified as meningitis or 
encephalitis by using a diverse set of clinical and laboratory 
definitions. The main causes of meningitis reported in Asia 
are Mycobacterium tuberculosis, Streptococcus pneumoni-
ae, Streptococcus suis, Neisseria meningitidis, and Cryp-
tococcus spp. (Appendix Table 1, https://wwwnc.cdc.gov/
EID/article/25/5/18-0914-App1.pdf). Physicians rarely 
consider rickettsial and leptospiral pathogens, but interest 
in these reemerging treatable etiologies is resurfacing (4). 
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in Asia. Japanese encephalitis virus (JEV) causes ≈68,000 
cases of encephalitis a year (5), and dengue virus is increas-
ingly reported as a cause of neurologic disease, occurring 
in 0.5%–6.2% of dengue patients (6–9). Other common vi-
ral causes of encephalitis include enterovirus and herpes 
simplex viruses (HSVs) 1 and 2 (10).
Few data globally are available to guide policy on the 
prevention, diagnosis, and treatment of CNS infections, 
and the diversity of definitions for different CNS infection 
syndromes is confusing (11); some case definitions use 
clinical criteria only (12,13), and others include additional 
laboratory variables (10,14). Meningitis (i.e., meningeal 
infection) and encephalitis (i.e., parenchymal infection) 
presumably represent a continuum, but the diversity of 
clinical and laboratory features and etiologies across this 
wide spectrum is poorly understood. The standard for dif-
ferentiating encephalitis from meningitis is histopathology, 
but biopsies and autopsies are rarely performed in Asia.
In Laos, the only comprehensive routine cerebrospi-
nal fluid (CSF) diagnostic service available is in the capital 
city, Vientiane, at Mahosot Hospital (15–17). After a pub-
lication reporting rickettsial and leptospiral pathogens as 
important causes of CNS infections in Laos (4), we present 
the results of the full investigation conducted on the causes 
of CNS infection in this hospital to guide public health pol-
icy and treatment guidelines.
Methods
Study Site and Patient Recruitment
This study was prospectively conducted (January 2003–
August 2011) with inpatients on all wards of Mahosot 
Hospital in Vientiane (17.959431°N, 102.613144°E, 188 
m above mean sea level), an ≈400-bed hospital providing 
primary, secondary, and tertiary care and admitting ≈2,000 
patients/month. We recruited inpatients of all ages for 
whom diagnostic lumbar puncture was indicated for sus-
picion of CNS infection because of altered consciousness 
or neurologic findings and for whom lumbar puncture was 
not contraindicated. For patient inclusion, we used no for-
mal definition for CNS infection; patient recruitment was at 
the discretion of the responsible physician, reflecting local 
clinical practice. We recorded patient history and examina-
tion findings on standardized forms.
Ethics Statement
We obtained verbal (2003–2006) or written (2006–2011) 
informed consent from all recruited patients or close rela-
tives. Ethics clearance was granted by the Ethical Review 
Committee of the Faculty of Medical Sciences, National 
University of Laos (Vientiane, Laos), and the Oxford Uni-
versity Tropical Ethics Research Committee (Oxford, UK).
Encephalitis and Meningitis Clinical Case Definitions
We classified febrile patients meeting the World Health 
Organization (WHO) criteria for encephalitis or menin-
gitis (Figure 1) (18) as patients with WHO clinical CNS 
(hereafter WHO CNS) infection. Because of the overlap-
ping WHO case definitions for encephalitis and meningitis, 
which both include a Glasgow Coma Scale (GCS) score 
<15 as criteria, we created additional classifications for 
febrile patients: those with stiff neck; reduced GCS score 
(<15), seizures, or both; stiff neck and reduced GCS score, 
seizures, or both; no stiff neck but reduced GCS score, sei-
zures, or both; and stiff neck, a GCS score of 15, and no 
seizures (Table 1).
Laboratory Tests
Cerebrospinal fluid (CSF) was collected from patients (≈8 
mL for adults [defined as patients >15 years of age], ≈3.5 
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Figure 1. WHO encephalitis 
and meningitis case definitions. 
*Definitions from WHO (18). 
†Defined here as a Glasgow 
Coma Scale score <15. ‡Not 
“with sudden onset of fever 
>38.5°C” as recommended 
by the WHO because we saw 
patients, especially young 
children, with meningitis but 
with temperatures below the 
WHO temperature criterion. 
§Patients with history of fever 
or documented fever (>37.5°C). 
¶History of neck stiffness or neck 
stiffness on examination. WHO, 
World Health Organization.
RESEARCH
mL for children 1–14 years of age, and ≈2.5 mL for chil-
dren <1 year of age), and opening pressure was recorded. 
Venous blood (≈18.5 mL for adults, 10 mL for children 
1–14 years of age, and 5.5 mL for children <1 year of age) 
was drawn on the same day. We aimed to collect ≈2 mL 
follow-up serum 7–10 days after lumbar puncture. Speci-
mens were transported to the laboratory within ≈30 minutes, 
and we aliquoted and immediately tested or stored them 
at −80°C. We submitted all patient samples for a panel of 
laboratory tests: complete blood count; biochemistry panel; 
culture; and serologic and molecular assays for a range of 
bacteria, viruses, parasites, and fungi (Table 2; Appendix). 
HIV-1 and HIV-2 rapid diagnostic tests were performed 
when indicated by the physician. Computed tomography 
brain scan was available starting in 2002 but rarely used, 
especially for intensive care patients, because of difficul-
ties transferring patients. Magnetic resonance imaging and 
electroencephalographic facilities were not available.
Interpretation
The confirmed etiology was determined by the results of 
a panel of diagnostic tests (Table 2), which included tests 
for the direct detection of pathogens in CSF or blood, 
specific IgM in CSF, seroconversion, or a 4-fold rise in 
antibody titer between admission and follow-up serum 
samples. Pathogen detection was confirmed after critical 
analysis of test results to rule out possible contamination. 
When evidence of >1 pathogen was obtained for a patient, 
we defined the confirmed etiology as detection by direct 
tests over indirect tests (antibody-based tests) and priori-
tized CSF detection over blood detection (39). We defined 
a confirmed co-infection as the direct (or indirect, if only 
indirect tests were positive) detection of >1 pathogen in the 
same matrix (CSF or blood).
Statistical Analyses
We compared patients with confirmed bacterial infec-
tion (including co-infections involving only bacteria) 
and patients with confirmed viral infection (including 
co-infections involving only viruses) with all other pa-
tients, excluding those with mixed co-infections (i.e. co-
infections with fungi or infections with both bacteria and 
viruses). We investigated the factors associated with death 
(died in hospital or discharged moribund), bacterial infec-
tion, or viral infection by univariate analysis using the χ2 
or Fisher exact test for categorical variables or the Mann-
Whitney U test for continuous variables. We analyzed the 
independent predictors of death, bacterial infection, and 
viral infection using multivariate logistic regression mod-
els. In multivariate analyses, we included all factors hav-
ing a p value <0.010 in the univariate analysis.
For variables with 6%–20% of the values missing, we 
executed multiple imputation models using chained equa-
tions and used a number of imputations that exceeded the 
highest proportion of missing values (40). We added age 
and sex to imputation models as auxiliary variables. We 
specified the imputation methods as linear for continuous 
normally distributed variables, logistic for binary variables, 
ordered logistic for ordinal variables, and predictive mean 
matching for continuous skewed variables. We performed 
logistic regression with the dependent variable (death, bac-
terial or viral infection) and all relevant covariates on each 
imputed data set and combined results using Rubin rules to 
take into account the variability in estimates among imputed 
data sets (41). Only variables that were significant (p<0.050) 
were retained in the final models. For comparison of analy-
sis methods, we provided the results using the correspond-
ing complete case analysis. We conducted analyses using 
Stata/SE version 14.0 (StataCorp, https://www.stata.com).
Results
Patients
In total, 1,065 inpatients with suspected CNS infection con-
sented to study participation (Appendix Figure 1); 80% were 
recruited from the pediatric and adult intensive care wards 
and adult infectious disease ward. On each ward, ≈8 physi-
cians were in charge of patient recruitment. All were general 
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Table 1. Classifications of febrile patients with clinical central nervous system infection (n = 771), Laos, January 2003–August 2011* 
Clinical sign 
No. (%) 
patients 
 
 Additional classification, % 
Stiff 
neck 
GCS score <15, seizure, or both Stiff neck + GCS 
score 15 + no 
seizure 
Stiff 
neck 
GCS 
score <15 Seizure 
WHO classification, %† 
All Stiff neck 
No stiff 
neck MEN E ME 
+   191 (24.8) 96.2    83.5    24.8 
+ +  244 (31.6) 75.2 71.5  75.2 58.8   
+ + + 171 (22.2)    
+  + 38 (4.9)    
 + + 57 (7.4)    16.5  
 +  41 (5.3)     
  + 29 (3.8)       
*Each line of the table corresponds to a given combination of criteria presented on the left side of the table. Each combination is then assigned (shaded 
cell) to >1 classifications (WHO and additional classifications) as defined in the Methods section. Green-shaded cells are the additional classifications 
used throughout our study. E, encephalitis; GCS, Glasgow Coma Scale; ME, meningoencephalitis; MEN, meningitis; WHO, World Health Organization; +, 
clinical sign present. 
†Definitions of WHO classification provided in Figure 1. 
 
Central Nervous System Infections, Laos
hospital or infectious disease physicians; none were neurolo-
gists. We collected information on patient demographics, 
clinical presentation, and blood and CSF parameters (Table 
3–4; Figure 2). More patients were recruited during the rainy 
season (Figure 3). The median time between admission and 
follow-up blood collection was 9 (interquartile range [IQR] 
6–16) days. One third (33.6%, 358/1,065) were children <15 
years of age (Table 3; Appendix Table 2).
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Table 2. Diagnostic laboratory tests used to confirm etiology in patients with suspected central nervous system infection, by sample 
type, Laos, January 2003–August 2011* 
Pathogens tested Cerebrospinal fluid† Blood 
Malaria pathogens None Giemsa thick and thin smear (if patient from 
endemic area) 
Leptospira spp. Hydrolysis probe real-time PCR (19) Culturing of blood clot on EMJH medium; 
microscopic agglutination test of admission and 
follow-up serum samples (4-fold rise considered 
positive result) (20); hydrolysis probe real-time 
RT-PCR from buffy coat (19) 
Cryptococcus spp. Indian ink stain; if HIV suspected, Cryptococcus 
Antigen Latex Agglutination Test (IMMY, 
http://www.immy.com); if Indian ink positive and 
HIV suspected, culture on Sabouraud agar 
None 
Mycobacterium tuberculosis Lowenstein-Jensen culture; auramine and Ziehl-
Neelsen stains 
None 
Rickettsia spp.‡ Hydrolysis probe real-time PCR (21,22) Hydrolysis probe real-time and conventional PCR 
from buffy coat (21,22); sequencing 
R. typhi, Orientia 
tsutsugamushi‡ 
Hydrolysis probe real-time PCR (21,23) Hydrolysis probe real-time PCR on buffy coat 
(21,23); IgM and IgG indirect immunofluorescent 
assay of admission and follow-up serum samples 
(4-fold rise considered positive result) (24) 
Community-acquired bacterial 
infection 
Gram stain; culture in blood agar and chocolate 
agar 
Blood culture bottle 
Streptococcus pneumoniae, 
Streptococcus suis, 
Haemophilus influenzae, 
Neisseria meningitidis 
Culture on blood agar, chocolate agar, and 
MacConkey plates (for patients <1 year of age);  
hydrolysis probe real-time RT-PCR (25–27) 
Blood culture bottle 
Dengue virus Hydrolysis probe real-time RT-PCR (28); NS1 
ELISA (Dengue Early ELISA, Panbio, 
https://www.alere.com); ELISA IgM (Japanese 
Encephalitis/Dengue IgM Combo ELISA, Panbio) 
Hydrolysis probe real-time RT-PCR on serum 
samples (28); NS1 ELISA on serum samples; 
ELISA IgM on admission and follow-up serum 
samples (assessed seroconversion) 
JEV§ ELISA IgM (Japanese Encephalitis/Dengue IgM 
Combo ELISA, Panbio) 
ELISA IgM on admission and follow-up serum 
samples (assessed seroconversion) 
Enterovirus, West Nile virus, 
influenza viruses A and B, 
Henipavirus 
Hydrolysis probe real-time RT-PCR (29–31) (in 
house) 
Hydrolysis probe real-time RT-PCR on serum 
samples (29–31) (in house) 
Flavivirus¶ SYBR Green real-time RT-PCR (32,33) SYBR Green real-time RT-PCR on serum 
samples (32,33) 
Herpes simplex virus 1 and 2, 
Varicella zoster virus, human 
cytomegalovirus 
Hydrolysis probe real-time RT-PCR (34–36) None 
Measles virus, mumps virus Hydrolysis probe real-time RT-PCR (37,38); if 
seropositive in blood sample, IgM ELISA with 
Enzygnost Anti-Measles Virus/IgM or Enzygnost 
Anti-Parotidis/IgM kits (Dade Behring, 
https://www.healthcare.siemens.com) 
Hydrolysis probe real-time RT-PCR on serum 
samples (37,38); IgM and IgG ELISAs: 
Enzygnost Anti-Measles Virus/IgM, Enzygnost 
Anti-Measles Virus/IgG, Enzygnost Anti-
Parotidis/IgM, and Enzygnost Anti-Parotidis/IgG 
kits (Dade Behring) (assessed seroconversion) 
HIV None Determine HIV-1/2 Combo (Alere, 
https://www.alere.com) or Uni-Gold HIV (Trinity 
Biotech, https://www.trinitybiotech.com) 
*See Appendix (https://wwwnc.cdc.gov/EID/article/25/5/18-0914-App1.pdf) for further details on methods. Cerebrospinal fluid and serum samples were 
inoculated on Vero and buffalo green monkey kidney cells for viral isolation. The median (interquartile range) interval between admission and follow-up 
serum sample collection was 9 (6–16) days. EMJH, Ellinghausen-McCullough-Johnson-Harris; JEV, Japanese encephalitis virus; NS1, nonstructural 
protein 1; RT-PCR, reverse transcription PCR. 
†Contraindications for lumbar puncture included focal neurologic signs on examination, clinical evidence for raised intracranial pressure, skin or soft 
tissue sepsis at the proposed puncture site, severe coagulopathy, or severe thrombocytopenia. 
‡Buffy coats were inoculated on Vero and L929 cells for O. tsutsugamushi and Rickettsia sp isolation. 
§Detection of JEV IgM in a single sample of serum is considered as laboratory confirmation according to World Health Organization criteria. However, in 
this study, to be conservative and consistent with interpretation of other test results, a single detection of JEV IgM in serum was not counted as confirming 
JEV central nervous system infection. 
¶Flavivirus RT-PCR would have likely detected the main flaviviruses circulating in Laos. 
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Of 476 adults tested for HIV, 118 (24.8%) were sero-
positive; of 227 children tested, 1 (0.4%) was seropositive. 
More than half (61.9%, 590/953) of patients had a history 
or hospital chart evidence of antibiotic use before lumbar 
puncture. Most (90.8%, 962/1,059) patients had a his-
tory of fever or documented admission fever. The median 
length of fever at admission was 4 (IQR 2–8) days. The 
most frequent symptoms and signs were headache (88.1%, 
787/893); neck stiffness (64.2%, 683/1,064); confusion 
(57.4%, 608/1,060); GCS score <15 (52.6%, 551/1,047); 
and vomiting, diarrhea, or both (54%, 575/1,064). All 
symptoms and signs were more frequent in children than 
adults (p<0.05), except headache, which was more frequent 
in adults (p = 0.023). Most (93.6%, 832/889) patients had 
CSF findings outside reference ranges (elevated CSF white 
cell count, elevated CSF lactate, elevated CSF protein, low 
CSF glucose, or any combination of these parameters) (Ta-
ble 4; Appendix Table 3, Figure 2).
Etiology was confirmed in 450 (42.3%) patients; 413 
(38.8%) had monoinfections and 37 (3.5%) co-infections 
(Appendix Tables 4–8). The identified monoinfections were 
JEV (8.8%, 94/1,065), Cryptococcus spp. (6.6%, 70/1,065; 
9 C. gattii), Orientia tsutsugamushi (2.9%, 31/1,065), 
dengue virus (2.5%, 27/1,065), Leptospira spp. (2.3%, 
25/1,065), Rickettsia spp. (2.3%, 24/1,065), S. pneumoniae 
(2.1%, 22/1,065), M. tuberculosis (1.9%, 20/1,065), HSV-
1 or HSV-2 (1.4%, 15/1,065), human cytomegalovirus 
(1.1%, 12/1,065), enterovirus (0.9%, 10/1,065), varicella 
902 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 25, No. 5, May 2019
 
Table 3. Demographic and clinical data at admission of patients with suspected CNS infection, by age group and etiology, Laos, 
January 2003–August 2011* 
Characteristic 
 
 
Etiology 
Age group 
Confirmed, 
n = 450 
None 
confirmed, 
n = 615 
Confirmed 
viral,  
n = 172 
Confirmed 
bacterial,  
n = 175 
All,  
n = 1,065 
Children,  
n = 358 
Adults,  
n = 707 
Demographic  
 M 666 (62.5) 207 (57.8) 459 (64.9)  288 (64.0) 378 (61.5) 111 (64.5) 117 (66.9) 
 F 399 (37.5) 151 (42.2) 248 (35.1)  162 (36.0) 237 (38.5) 61 (35.5) 58 (33.1) 
 Age, y, median (IQR) 23 (8–38) 3 (0.41–8) 32 (24–47)  23 (10–38) 24 (6–40) 16 (7–28) 23 (9–45) 
History  
 HIV seropositive, n = 703 119 (16.9) 1 (0.4) 118 (24.8)  75 (27.1) 44 (10.33) 8 (8.0) 6 (6.2) 
 Diabetes, n = 850 24 (2.8) 0 24 (4.2)  12 (3.5) 12 (2.4) 1 (0.8) 10 (7.5) 
 Antibiotic use before lumbar  
 puncture, n = 953 
590 (61.9) 238 (71.9) 352 (56.6)  252 (64.0) 338 (60.5) 109 (69.9) 100 (62.5) 
Signs and symptoms  
 Days of fever at admission,  
 median (IQR), n = 1,058 
4 (2–8) 4 (2–6) 5 (2–10)  5 (3–10) 4 (1–7) 5 (3–7) 5 (3–8) 
 Fever, n = 1,059 962 (90.8) 340 (95.2) 622 (88.6)  425 (94.9) 537 (87.9) 162 (95.3) 171 (97.7) 
 Headache,† n = 893 787 (88.1) 155 (83.3) 632 (89.4)  369 (92.5) 418 (84.6) 139 (90.9) 135 (91.2) 
 Hearing loss,† n = 893 51 (5.7) 10 (5.4) 41 (5.8)  20 (5.0) 31 (6.3) 8 (5.2) 7 (4.7) 
 Dysuria,† n = 891 28 (3.1) 4 (2.2) 24 (3.4)  10 (2.5) 18 (3.7) 3 (2.0) 3 (2.0) 
 Visual loss,† n = 885 66 (7.5) 14 (7.7) 52 (7.4)  23 (5.8) 43 (8.8) 11 (7.2) 5 (3.4) 
 Diplopia,† n = 889 36 (4.1) 4 (2.2) 32 (4.5)  15 (3.4) 21 (4.3) 6 (4.0) 6 (4.1) 
 Photophobia, n = 850 52 (5.8) 14 (7.4) 38 (5.4)  23 (5.8) 29 (5.9) 7 (4.6) 10 (6.8) 
 Focal neurologic signs, n = 939 22‡ (2.3) 5 (1.6) 17 (2.7)  8 (2.1) 14 (2.5) 1 (0.7) 6 (4.1) 
 Neck stiffness, n = 1,064 683 (64.2) 245 (68.4) 438 (62.0)  316 (70.2) 367 (59.8) 130 (75.6) 128 (73.1) 
 Confusion, n = 1,060 608 (57.4) 232 (65.5) 376 (53.3)  254 (56.7) 354 (57.8) 114 (66.3) 103 (59.5) 
 Convulsions, n = 1,063 319 (30.0) 233 (65.3) 86 (12.2)  119 (26.5) 200 (32.6) 65 (37.8) 44 (25.3) 
 GCS score, median (IQR), n = 1,010 14 (11–15) 14 (10–15) 15 (11–15)  15 (11–15) 14 (10–15) 13 (10–15) 14 (11–15) 
 GCS score <15,§ n = 1,047 551 (52.6) 220 (63.4) 331 (47.3)  225 (50.5) 326 (54.2) 101 (59.4) 94 (54.0) 
 WHO clinical CNS infection,¶  
 n = 1,040 
771 (74.1) 313 (90.7) 458 (65.9)  341 (77.0) 430 (72.0) 143 (85.1) 140 (80.9) 
Outcome  
 Days of hospitalization, n = 846,  
 median (IQR) 
9 (5–14) 8 (5–13) 10 (5–15.5)  11 (6–17) 8 (5–13) 10 (6–14) 11 (7–17) 
 Death,# n = 893 235 (26.3) 70 (22.5) 165 (28.4)  94 (25.0) 141 (27.3) 23 (15.7) 43 (27.9) 
*Values are no. (%) unless indicated otherwise. We defined children as patients <15 years of age and adults >15 years of age. History or physical 
examination or both, were taken into account for confusion, neck stiffness, photophobia, fever (history of fever or >37.5ºC during physical examination). In 
total, 8 women in the patient population were pregnant; 26 (2.4%) patients had computed tomography brain scans, and 2 of these scans demonstrated 
brain abscesses. The confirmed viral group includes patients infected with multiple viruses, and the confirmed bacterial group includes patients infected 
with multiple bacteria. CNS, central nervous system; GCS, Glasgow Coma Scale; IQR, interquartile range; WHO, World Health Organization.  
†Data from children <3 years of age were considered not reliable and were thus excluded from analysis.  
‡Of these patients, 7 had hemiplegia, 11 had limb weakness, and 1 had paraplegia; 13 patients had admission or discharge diagnoses of Guillain-Barre 
syndrome. Retrospective evaluation of the likelihood of this diagnosis by using the Brighton system suggested that 4 patients met level 3 criteria for 
Guillain-Barre syndrome diagnostic certainty (42). 
§Includes confused and disoriented patients. 
¶Defined as fever with GCS score <15, neck stiffness (history of or present during examination), or history of seizures or any of these signs in 
combination. Patients with missing data for 1 of these criteria were not counted. 
#Includes patients who died at the hospital and those taken home to die. 
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zoster virus (0.6%, 6/1,065), mumps virus (0.5%, 5/1,065), 
and Plasmodium falciparum (0.4%, 4/1,065). Other bac-
teria were detected in 48 (4.5%) patients (Figure 4; Ap-
pendix Table 5). All samples were negative for West Nile 
virus, influenza A and B, Henipavirus, and measles virus 
by PCR. Infection by M. tuberculosis, Cryptococcus spp., 
or varicella zoster virus was not detected in children (Ap-
pendix Table 8). The median age of children with enterovi-
rus infection was 4.5 (IQR 1–11) years and JEV infection 
13 (IQR 8–20) years. The proportion of patients with JEV 
infection was higher for children (14%, 50/358) than adults 
(6%, 44/707, p<0.001). Significantly more enterovirus pa-
tients (80%) than nonenterovirus patients (33%; p = 0.002) 
were children.
Factors Associated with Bacterial and Viral Infections
We compared patients with single (n = 170) or multiple 
(n = 5) bacterial infections (excluding co-infections with 
viruses or fungi) with all other patients (n = 875). Factors 
significantly associated with bacterial infections on univar-
iate analysis (p<0.01; Appendix Table 9) were included in 
multivariate analysis. Diabetes (adjusted odds ratio [aOR] 
3.1, 95% CI 1.2−7.7), history of fever or fever at admission 
(aOR 3.9, 95% CI 1.4-11.1), higher serum C-reactive pro-
tein (aOR 1.08, 95% CI 1.05-1.11), and higher CSF lactate 
(aOR 3.5, 95% CI 2.3−5.4) were independent predictors of 
bacterial infection (Appendix Table 10).
We compared patients with single (n = 169) or mul-
tiple (n = 3) viral infections (excluding co-infections with 
bacteria or fungi) with all other patients (n = 867). Factors 
significantly associated with viral infections on univariate 
analysis (p<0.01; Appendix Table 11) were included in 
multivariate analysis. Neck stiffness (aOR 1.9, 95% CI 1.3-
2.8) and higher hematocrit (aOR 1.4, 95% CI 1.1-1.9) were 
associated with viral infection, whereas higher CSF lactate 
(aOR 0.3, 95% CI 0.1–0.5), older age (aOR 0.8, 95% CI 
0.7–0.9), and longer interval between admission and lum-
bar puncture (aOR 0.9, 95% CI 0.8–1.0) were negatively 
associated with viral infection (Appendix Table 12).
Relationships between Clinical Presentation and Etiology
In total, 771 (74.1%) of 1,040 patients had WHO CNS in-
fection; 44.2% of these patients had confirmed etiologies 
compared with 37.9% of patients not fulfilling WHO CNS 
infection criteria (p = 0.063; Appendix Table 13). Because of 
the considerable overlap between the WHO encephalitis and 
meningitis definitions, 551 (71.5%) patients were classified 
as having meningoencephalitis. Therefore, we analyzed the 
frequency of neck stiffness, reduced GCS score, and seizures 
among febrile patients with clinical CNS infection (Table 1).
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Table 4. Characteristics of peripheral blood and cerebrospinal fluid at admission of patients with suspected central nervous system 
infection, by age group and etiology, Laos, January 2003–August 2011* 
Sample type and parameter 
Age group 
 
Etiology 
All, n = 
1,065 
Children, 
n = 358 
Adults, n 
= 707 
Confirmed, 
n = 450 
None 
confirmed, 
n = 615 
Confirmed 
viral,  
n = 172 
Confirmed 
bacterial,  
n = 175 
Peripheral blood   
 Elevated white cell count,† n = 952 449 (47.2) 150 (47.9) 299 (46.8)  198 (49.0) 251 (45.8) 84 (53.9) 84 (53.5) 
 Low white cell count, n = 952 45 (4.7) 22 (7.0) 23 (3.6)  22 (5.5) 23 (4.2) 6 (3.9) 7 (4.5) 
 Anemia, n = 948 355 (37.5) 112 (35.7) 243 (38.3)  160 (39.8) 195 (35.7) 44 (28.2) 68 (43.9) 
 Thrombocytopenia, n = 649 55 (8.5) 16 (6.8) 39 (9.4)  22 (7.8) 33 (9.0) 4 (3.5) 12 (10.6) 
 Elevated C-reactive protein, n = 868 547 (63.0) 145 (51.6) 402 (68.5)  265 (69.2) 282 (58.1) 98 (64.9) 114 (79.7) 
 Hyperglycemia,† n = 991 237 (23.9) 81 (25.8) 156 (23.0)  105 (24.5) 132 (23.5) 40 (24.0) 53 (32.3) 
 Severe hyperglycemia,† n = 991 72 (7.3) 26 (8.3) 46 (6.8)  35 (8.2) 37 (6.6) 12 (7.2) 22 (13.4) 
 Elevated serum sodium,‡ n = 807 225 (27.9) 45 (17.8) 180 (32.5)  82 (22.8) 143 (31.9) 40 (28.6) 26 (19.4) 
 Low serum sodium,‡ n = 807 63 (7.8) 31 (12.3) 32 (5.8)  31 (8.6) 32 (7.1) 8 (5.7) 16 (11.9) 
Cerebrospinal fluid  
 Turbid, n = 999 145 (14.5) 40 (12.2) 105 (15.7)  80 (18.4) 65 (11.5) 21 (12.4) 38 (23.2) 
 Elevated opening pressure, n = 977 334 (34.2) 86 (27.6) 248 (37.3)  155 (36.4) 179 (32.5) 42 (24.9) 60 (37.3) 
 Elevated white cell count,§ n =  975 729 (74.8) 237 (74.8) 492 (74.8)  341 (80.2) 388 (70.6) 141 (84.9) 129 (80.1) 
 Elevated lymphocyte count, n = 890 467 (52.5) 149 (51.2) 318 (53.1)  234 (59.5) 233 (46.9) 106 (68.4) 91 (62.3) 
 Elevated neutrophil count, n = 889 644 (72.4) 213 (73.5) 431 (72.0)  309 (78.8) 335 (67.4) 130 (83.9) 116 (80.0) 
 Elevated eosinophil count,¶ n = 1,001 46 (4.6) 7 (2.1) 39 (5.8)  11 (2.5) 35 (6.2) 9 (5.3) 2 (1.2) 
 Elevated protein, n = 955 601 (62.9) 177 (57.3) 424 (65.6)  281 (66.9) 320 (59.8) 112 (66.3) 108 (69.7) 
 Decreased glucose, n = 957 280 (29.3) 58 (18.8) 222 (34.3)  138 (32.8) 142 (26.5) 45 (26.6) 51 (32.9) 
 Decreased cerebrospinal fluid: venous     
    glucose ratio, n = 929 
540 (58.1) 159 (54.8) 381 (59.6)  253 (61.7) 287 (55.3) 97 (58.8) 97 (64.2) 
 Elevated lactate, n = 985 650 (66.0) 217 (67.8) 433 (65.1)  298 (69.8) 352 (63.1) 93 (56.0) 132 (80.5) 
*Values are no. (%). We defined children as patients <15 years of age and adults >15 years of age. The confirmed viral group includes patients infected 
with multiple viruses, and the confirmed bacterial group includes patients infected with multiple bacteria. Elevated and low parameters mean above or 
below reference ranges. Anemia is defined as hematocrit below reference range. Thrombocytopenia is defined as platelet count below reference range. 
See Appendix Table 3 (https://wwwnc.cdc.gov/EID/article/25/5/18-0914-App1.pdf) for reference ranges. CSF, cerebrospinal fluid. 
†Hyperglycemia was defined as a blood glucose level of >7.7 mmol/L and severe hyperglycemia as a blood glucose level >11.1 mmol/L. 
‡Serum sodium levels >150 mmol/L were considered elevated and <130 mmol/L considered low; 5 patients (0.6%) had serum sodium <115 mmol/L. 
§Samples with high turbidity could not be counted and were thus not included. 
¶An eosinophil count >10% was considered elevated. 
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When comparing viral and bacterial infections, we 
observed no significant differences (p>0.05) in the propor-
tions of encephalitis and meningitis syndromes, although 
differences were observed for some specific etiologies 
(Figure 4). In total, 90 (53.6%) febrile patients with vi-
ral infection and 86 (49.7%) with bacterial infection had 
neck stiffness and reduced GCS score, seizures, or both; 
17 (10.1%) patients with viral infection and 16 (9.3%) with 
bacterial infection had reduced GCS score, seizures, or 
both without neck stiffness; and 36 (21.4%) patients with 
viral infection and 38 (22.0%) with bacterial infection had 
neck stiffness, a GCS score of 15, and no seizures (Figure 
4). We obtained similar results using the WHO definitions. 
In total, 25 (14.9%) patients with viral infection and 33 
(19.1%) with bacterial infection did not fulfill the WHO 
CNS infection definition.
In comparison with the distribution of syndromes ob-
served for all patients, the distribution in patients with some 
etiologies were significantly different (p<0.05). Of the 89 
JEV patients with WHO CNS infection, 75.3% had fever; 
neck stiffness; and reduced GCS score, seizures, or both. 
Of the 26 O. tsutsugamushi patients with WHO CNS infec-
tion, 50% had fever, neck stiffness, a GCS score of 15, and 
no seizures. Of note, almost half (47.8%) of the patients 
with cryptococcal infection did not fulfill the definition for 
WHO CNS infection, and of the 36 who did, 55.6% had 
fever, neck stiffness, a GCS score of 15, and no seizures.
Risk Factors for Death
Of 893 patients, 235 (26.3%) died, including those dis-
charged moribund; we compared them to the 658 (73.7%) 
patients discharged alive and not moribund. For factors sig-
nificantly associated with death (p<0.01; Appendix Table 
14) in the univariate analysis, we conducted multivariate 
analysis. The variables strongly associated with death were 
higher CSF lactate (aOR 1.1, 95% CI 1.0–1.1) and reduced 
GCS score (aOR 0.8, 95% CI 0.8–0.9). Patients with vi-
ral infection were less likely to die than those with other 
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Figure 2. Distribution of clinical 
manifestations among patients 
with suspected CNS infection, 
by age group and etiology, Laos, 
January 2003–August 2011. 
A) WHO criteria; B) additional 
criteria (Table 1). Children were 
patients <15 years of age and 
adults patients >15 years of age. 
Numbers above bars indicate 
number of patients in group. 
CNS, central nervous system; 
GCS, Glasgow Coma Scale; 
WHO, World Health Organization.
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diagnoses (aOR 0.4, 95% CI 0.3–0.7) (Appendix Table 15). 
Diabetes and hyperglycemia (glucose >7.7 mmol/L) at ad-
mission were not associated with death.
Indications for Antibiotic Treatment
In total, 56 patients (12.4% of the 450 patients with con-
firmed etiologies) were infected with bacteria treatable by 
ceftriaxone and 64 patients (14.2% of the patients with con-
firmed etiologies) with bacteria treatable by doxycycline 
but not ceftriaxone (Table 5). Twenty-eight patients were 
infected with a Leptospira spp. treatable by ceftriaxone or 
doxycycline, but 2 were co-infected with O. tsutsugamu-
shi not treatable by ceftriaxone. Of 142 patients infected 
by bacteria treatable by ceftriaxone or doxycycline, 89 
(62.7%) received appropriate treatment, 17% (13/77) of 
whom died. In comparison, 25% (12/48) of the patients 
who did not receive appropriate treatment died (p = 0.270).
Including the 450 patients with confirmed diagnoses, 
we analyzed the criteria for bacterial meningitis commonly 
considered when making decisions on antibiotic treatment: 
elevated CSF white cell count, elevated CSF lactate, ele-
vated CSF protein, decreased CSF glucose, reduced GCS 
score, turbid CSF, and neck stiffness. A low percentage 
(<23%) of patients with any 1 of these criteria (except 
turbid CSF, 38.8%) or a combination of these criteria had 
bacterial infections treatable by ceftriaxone or doxycycline 
(Appendix Table 16). Furthermore, only 1 combination 
of criteria (elevated C-reactive protein, elevated CSF pro-
tein, or elevated CSF lactate or any combination of these 
criteria) could identify all patients infected with bacteria 
treatable by ceftriaxone (Table 5). However, because only 
5% of our patient series did not display this combination of 
criteria, none of the analyzed clinical and biological results 
can be reliably used to guide decisions on antibiotic use.
Discussion
Etiology was confirmed in 42.3% of patients with suspect-
ed CNS infection, consistent with regional published data 
(Appendix Table 1); 16.2% had viral infections, and 16.4% 
had bacterial infections. We observed no significant differ-
ences in the distribution of clinical encephalitis and men-
ingitis syndromes by bacterial or viral etiology; the most 
common infections in this patient population were JEV 
(8.8%) and Cryptococcus spp. (6.6%).
The results of this study provided evidence for the 
implementation of pneumococcal immunization in 2011 
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Figure 3. Recruited patients 
with suspected central nervous 
system infection, by month, Laos, 
January 2003–August 2011. A) 
Total patients recruited by month 
cumulating all studied years. B) 
Patients recruited each month 
of each year. Light and dark 
shades of colors were used in 
an alternating pattern to facilitate 
graph reading.
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and JEV immunization in 2013 in Laos (16,17). Although 
the main etiology reported among patients with suspected 
CNS infection was JEV, this finding might be an overesti-
mate; we have noted that the detection of JEV IgM in CSF 
has low predictive value (44). On the other hand, bacterial 
causes were probably underestimated; 61.9% of patients 
were known or thought to have received an antibiotic be-
fore lumbar puncture, potentially rendering bacteria uncul-
tivable or reducing the bacterial load below the threshold 
needed for molecular detection.
The mortality rate we report in our study (26.3%) was 
higher than those reported in similar studies in neighboring 
countries (≈10%; Appendix Table 1). Ineffective patient 
management or inappropriate treatment through lack of pre-
vious local data might have caused this higher mortality rate. 
The epidemiology of CNS infection varies by geography; 
therefore, regional evidence should be used to build region-
al policies on prevention, diagnosis, and treatment of these 
infections.
In this study, 17% (119/703) of the patients tested were 
HIV seropositive. The highest proportion of HIV-seropos-
itive patients was among those with cryptococcal infection 
(79%; Appendix Table 7). However, only 66% (703/1,065) 
of patients were tested. More patients need to receive HIV 
testing in Laos, and more investigations on the relationship 
between HIV and other infections are needed.
Our study had a number of limitations, including the 
partial use of stored samples; missing values; a low fre-
quency of computed tomography brain scans and HIV 
testing; and a lack of magnetic resonance imaging, brain 
or postmortem examination, and diagnostics for autoim-
mune and eosinophilic CNS disease (45,46) and other 
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Figure 4. Distribution of clinical presentations in patients with suspected central nervous system infection, by confirmed etiology, Laos, 
January 2003–August 2011. Analysis per pathogen includes only patients with monoinfections. Other bacteria include 7 Escherichia coli, 
4 Streptococcus agalactiae, 4 Neisseria meningitidis, 1 Salmonella enterica group D, 1 S. enterica group B or C, 5 S. enterica serovar 
Typhi, 4 Streptococcus suis, 3 Klebsiella pneumoniae, 7 Haemophilus influenzae type b, 5 Burkholderia pseudomallei, 6 Staphylococcus 
aureus, and 1 Morganella morganii. Blue font indicates viruses, red font indicates bacteria, and black font indicates fungi. CNS, central 
nervous system; GCS, Glasgow Coma Scale; WHO, World Health Organization.
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pathogens (e.g., Toxoplasma gondii, Mycoplasma spp., 
and Zika virus). The absence of strict criteria for the 
inclusion of patients could have resulted in recruitment 
bias; however, the data reflect real-life medical practice. 
The proportion of patients who declined lumbar punc-
ture is unknown. Almost all patients (93.6%) had CSF 
findings outside reference ranges. Although published 
data on this combined index are few, the proportion of 
patients with abnormal CSF findings is generally lower 
in routine practice (e.g., <40% at La Timone Hospi-
tal, Marseille; L. Ninove and J. Fromonot, La Timone 
Hospital, pers. comm., March 2017). This finding sug-
gests a relatively low frequency of lumbar puncture at 
Mahosot Hospital, reflecting current practice but repre-
senting an unknown proportion of all patients admitted 
with CNS disease. The sample size was too small for a 
comparison of mortality rates between treated and non-
treated patients.
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Table 5. Frequency of criteria consistent with bacterial meningitis among patients with suspected central nervous system infection, by 
etiology and antibiotic susceptibility, Laos, January 2003–August 2011* 
Variables 
Patients with confirmed etiology, n = 450 
Patients 
without 
confirmed 
etiology,  
n = 615 
Total,  
n = 1,065 All 
Patients infected by bacteria treatable by† 
Other,  
n = 305 
Ceftriaxone 
 
Doxycycline 
Not including 
Leptospira 
infections,  
n = 56‡ 
Including 
Leptospira 
infections, 
n = 84 
Not including 
Leptospira 
infections,  
n = 64§ 
Including 
Leptospira 
infections, 
n = 90 
Neck stiffness¶ 316 (70.2) 41 (73.2) 60 (71.4)  46 (71.9) 63 (70.0) 213 (69.8) 367 (59.8) 683 (64.2) 
GCS score <15 225 (50.5) 34 (61.8) 47 (56.6)  27 (42.2) 40 (44.4) 152 (50.3) 326 (54.2) 551 (52.6) 
Elevated CRP 265 (69.2) 44 (91.7) 60 (87.0)  36 (70.6) 51 (72.9) 171 (64.3) 282 (58.1) 547 (63.0) 
CSF turbid 80 (18.4) 27 (49.1) 31 (37.8)  6 (10.7) 9 (11.1) 45 (15.1) 65 (11.5) 145 (14.5) 
Elevated CSF lactate 298 (69.8) 44 (83.0) 63 (78.8)  44 (74.6) 62 (73.8) 193 (66.3) 352 (63.1) 650 (66.0) 
Elevated CSF protein 281 (66.9) 44 (81.5) 57 (73.1)  32 (62.7) 43 (58.9) 195 (66.3) 320 (59.8) 601 (62.9) 
Decreased CSF glucose 138 (32.8) 23 (42.6) 26 (33.3)  12 (23.5) 15 (20.5) 101 (34.2) 142 (26.5) 280 (29.3) 
Decreased CSF:venous 
glucose ratio 
253 (61.7) 40 (76.9) 49 (64.5)  27 (54) 35 (48.6) 179 (62.4) 287 (55.3) 540 (58.1) 
Elevated CSF leukocyte 
count# 
341 (80.2) 44 (86.3) 64 (82.1)  39 (69.6) 57 (70.4) 241 (82.0) 388 (70.6) 729 (74.8) 
Combinations of >1 of the above findings 
 Elevated CSF lactate, 
 protein, leukocyte  
 count; decreased CSF  
 glucose; CSF turbid# 
418 (95.9) 53 (96.4) 76 (93.8)  54 (90.0) 75 (89.3) 291 (97.7) 534 (93.2) 952 (94.4) 
 Elevated CRP;  
 elevated CSF lactate,  
 protein; CSF turbid 
427 (96.4) 56 (100) 82 (100)  59 (92.2) 83 (94.3) 289 (96.3) 526 (93.4) 953 (94.7) 
 Elevated CRP;  
 elevated CSF lactate,  
 protein 
425 (95.4) 56 (100) 82 (100)  58 (92.1) 82 (94.3) 288 (96.3) 525 (93.4) 950 (94.7) 
 Elevated CRP;  
 elevated CSF lactate 
385 (91.2) 54 (98.2) 78 (98.7)  56 (91.8) 78 (94.0) 254 (89.1) 478 (88.5) 863 (89.7) 
 Elevated CRP;  
 elevated CSF protein 
382 (90.1) 54 (98.2) 75 (94.9)  49 (89.1) 68 (88.3) 261 (89.1) 442 (84.2) 824 (86.8) 
 Elevated CRP; GCS 
 score <15 
348 (83.9) 50 (100.0) 72 (98.6)  49 (86.0) 70 (89.7) 229 (79.5) 448 (83.1) 796 (83.4) 
 GCS score <15;  
 elevated CSF protein  
348 (81.1) 49 (90.7) 68 (85.0)  44 (77.2) 61 (75.3) 239 (81.0) 454 (80.8) 802 (80.9) 
 GCS score <15;  
 elevated CSF lactate 
361 (84.1) 48 (88.9) 69 (85.2)  50 (83.3) 70 (82.4) 244 (83.8) 466 (80.3) 827 (82.0) 
 GCS score <15;  
 elevated CSF lactate,  
 protein 
404 (92.9) 52 (94.5) 75 (91.5)  53 (88.3) 74 (87.1) 279 (94.3) 515 (89.4) 919 (90.9) 
*All values are no. (%). See Appendix Table 3 (https://wwwnc.cdc.gov/EID/article/25/5/18-0914-App1.pdf) for reference ranges. Only patients with 
confirmed etiology strictly sensitive to ceftriaxone or doxycycline are included in the analysis. Classification was based on a combination of susceptibility 
testing of isolates from patients and information from Principles and Practice of Infectious Diseases (43). Patients who were confused or disoriented who 
had their GCS score missing were considered to have a GCS score <15. CRP, C-reactive protein; CSP, cerebrospinal fluid; GCS, Glasgow Coma Scale. 
†In total, 28 patients were infected with Leptospira spp. treatable by either ceftriaxone or doxycycline, but 2 were also co-infected with Orientia 
tsutsugamushi not treatable with ceftriaxone. One patient co-infected with Streptococcus suis and Rickettsis typhi required therapy with both ceftriaxone 
and doxycycline. 
‡Includes 24 patients infected with Streptococcus pneumoniae and 32 infected with other bacteria (7 Escherichia coli, 4 Group B Streptococcus, 4 
Neisseria meningitidis, 1 Salmonella enterica group D, 1 S. enterica group B or C, 5 S. suis, 5 S. enterica serovar Typhi, 2 Klebsiella pneumoniae, 2 
Haemophilus influenzae, and 1 Edwardsiella tarda). 
§Includes 31 patients with Rickettsia spp. infection and 33 with O. tsutsugamushi infection. 
¶History of neck stiffness or neck stiffness on examination. 
#Samples with high turbidity could not be counted and were thus not included. 
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Although CNS infection is a global public health 
burden, global consensus on the case definition is lacking 
(Appendix Table 17). In clinical studies, encephalitis and 
meningitis have been studied separately or together (11), 
and CSF findings might or might not be taken into account 
(e.g., CSF findings are not part of the WHO criteria). There 
is confusion regarding the clinical and laboratory defini-
tions of encephalitis and meningitis, so we suggest pairing 
clinical, laboratory, or clinicolaboratory with these terms 
to reduce confusion. Further, altered consciousness and al-
tered mental status, shared by encephalitis and meningitis 
in many definitions, are undefined in the WHO definitions. 
We used GCS score <15 to define both objectively, but this 
practice resulted in considerable overlap in clinical defini-
tions: 71.4% of patients had WHO-defined meningitis and 
53% WHO-defined meningoencephalitis. When we re-
stricted the definition of meningitis to the presence of fever 
and neck stiffness, 61.9% of patients fulfilled those criteria; 
43.6% had neck stiffness combined with low GCS score, 
seizures, or both.
Studies on the clinical and etiologic characteristics of 
patients requiring lumbar puncture in Asia have usually 
focused on particular pathogens or just meningitis or en-
cephalitis (Appendix Table 1) (47). Although needed for 
treatment trials and pathophysiologic research, our data 
call into question the validity of defining criteria for patient 
management differently between encephalitis and meningi-
tis (Figure 4; Appendix Table 13). In Laos, evidence sug-
gests that brain (encephalitis) and meningeal (meningitis) 
infections have no clear distinguishable clinical manifes-
tations relating to the responsible pathogen and that these 
classifications should be used with caution in the Asia trop-
ics for guiding patient management.
We found that history of diabetes was independently 
associated with bacterial CNS infection. Indeed, some 
evidence suggests that diabetes is a risk factor for bacte-
rial CNS disease (48) and poor outcome in tuberculous 
meningitis (49). In univariate analysis, higher blood glu-
cose level was also associated with bacterial infection 
(p<0.001). Of 237 patients with hyperglycemia at admis-
sion (>7.7 mmol/L), 16 (6.8%) had a history of diabetes 
and 164 (69.2%) did not. Without convalescent glucose 
and hemoglobin A1c assays, however, we were unable to 
distinguish hyperglycemia resulting from severe disease 
or undiagnosed diabetes that might have predisposed to 
CNS infection. Intensive euglycemia management is dif-
ficult; can lead to hypoglycemia, especially in uncon-
scious patients; and requires skilled dedicated nursing 
that is not available in hospitals in rural Asia. Whether 
such intensive therapy would save lives remains uncer-
tain, but the development of an inexpensive computer-
ized algorithm technology for resource-poor settings to 
facilitate safe euglycemia management (50) should be 
a priority for investigation of efficacy. The burgeon-
ing global prevalence of diabetes calls for research re-
garding the relationship between hyperglycemia and 
CNS infections and optimizing their combined manage-
ment (48).
Our data suggest that patient survival could be im-
proved through 2 patient management interventions, the 
implementation of antibiotic use guidelines and strength-
ening of high-dependency units. The finding that poor 
outcomes were associated with a decreased GCS score at 
admission suggests that high-dependency units (a likely 
cost-effective intervention) could be used to enhance sup-
portive care for unconscious patients with CNS infection. 
Creating these units and incorporating them into care could 
improve outcomes and reduce the burden of intensive 
care unit treatment for these patients. More investigation 
is needed on the efficacy and cost-effectiveness of high-
dependency units in different contexts.
Ceftriaxone is conventionally used in Laos as a first-
line treatment for CNS bacterial infection but lacks efficacy 
for emerging rickettsial pathogens, for which doxycycline 
is recommended (4). Because delays in antibiotic therapy 
could result in severe consequences for patients, the deci-
sion for administering these drugs is made on the basis of 
clinical signs and laboratory results at admission. However, 
in Laos, we found that no variable, even in combination, 
could permit objective selection of appropriate antibiot-
ics. Therefore, the administration of early first-line empiric 
treatment with ceftriaxone and doxycycline for all patients 
with suspected CNS infection might save patient lives in 
Laos and elsewhere in rural Asia (4).
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